Sangamo Therapeutics Files for Chapter 11 Bankruptcy, Strikes Asset Deals with Eli Lilly and Astellas
The deals cover key gene therapy platforms and the Fabry disease program in a court-supervised auction.
/ 1649 items
#XY↓
Zcash Miner Fortitude to List on Nasdaq Through Merger with HeartSciences
The combined company will list on Nasdaq under the ticker TUDE in H2 2026.
Serapha Bio to Go Public via Merger with Boundless Bio, Raising $230 Million
Boundless Bio and Serapha Bio announce a merger and $230 million private placement. The combined company will advance SERP-01, a base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).
MacroGenics to Receive $24.5 Million Milestone Payment from Sanofi Following FDA Approval of TZIELD for Stage 3 Type 1 Diabetes
MacroGenics receives $24.5 million from Sanofi after FDA expands TZIELD approval to children aged 8-17 with newly diagnosed stage 3 Type 1 diabetes.
Profit-Taking Hits Moderna Stock After mRNA-1010 Wins Unanimous FDA Panel Backing
Decision due Aug 5, 2026. Potential 2026–27 launch.
Praxis Precision Medicines Wins FDA Breakthrough Status for Elsunersen in Rare Epilepsy
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.